Transitioning Your Drug from a Vial to Combination Product

It is becoming increasingly common for pharma and biotech companies to have a clearly defined strategy to transition their drug from a vial into a combination product format to enhance patient experience as well as achieve favorable market positioning for their drug. However, with drug and device development following different tracks and not always matched up from a timeline standpoint, it is critical to align both pathways and ensure optimal integration by taking several vital considerations into account.